​

Funding Round

Series B - Mirvie

Series B - Mirvie

Investment Firm

Overview

Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.

Announced Date

May 17, 2022

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Decheng Capital

Decheng Capital

Decheng Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

9

Investor Name
Participant InvestorMayfield Fund
Participant InvestorGoogle Ventures
Participant InvestorGeneral Catalyst
Participant InvestorKhosla Ventures
Participant InvestorBlackRock

Round Details and Background

Mirvie raised $45000000 on 2022-05-17 in Series B

Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 01, 2018
Series A - Mirvie
1-5.8M
May 17, 2022
Series B - Mirvie
9-45.0M
May 17, 2022
Debt Financing - Mirvie
1-15.0M
Aug 02, 2023
Grant - Mirvie
-4.6M

Recent Activity

There is no recent news or activity for this profile.